Temsujohn

Prodotti simili

Flomax

Prezzo da €46.66

Vedi

Veltride

Prezzo da €18.66

Vedi

Super Tadapox

Prezzo da €86.53

Vedi

MaxGun Sublingual Spray

Prezzo da €76.35

Vedi

Snovitra Soft

Prezzo da €20.36

Vedi

Finax

Prezzo da €43.27

Vedi

Temsujohn: Clinical Observations on a Novel Combination Therapy for Metabolic Syndrome and Chronic Inflammation - A Practitioners Report

Introduction: What is Temsujohn? Its Role in Modern Medicine

Look, I’ve been practicing internal medicine for almost twenty years, and I’ve seen the supplement market go through phases. Most products come and go. But when I first encountered Temsujohn about three years ago at a metabolic health conference in Milan, I was skeptical. The name itself sounded like a pharmaceutical compound, not a dietary supplement.

Temsujohn is a fixed-dose combination dietary supplement, formulated as a gastro-resistant tablet. Its primary claim is the synergistic management of metabolic syndrome components—specifically insulin resistance, non-alcoholic fatty liver disease (NAFLD), and low-grade systemic inflammation. It combines three well-studied botanical and mineral agents: Berberine HCl, Silymarin (from milk thistle), and Chromium Picolinate.

What makes it different isn’t the novelty of the ingredients, but the delivery system. The manufacturer spent considerable R&D on a dual-release matrix. The outer layer releases Silymarin rapidly for hepatic antioxidant effect, while the inner core delivers Berberine and Chromium in the small intestine, bypassing some of the gastric degradation that plagues standard Berberine formulations.

I started prescribing it cautiously. Now, it’s a staple in my practice for a specific subset of patients.

Key Components and Bioavailability

The composition is deceptively simple, but the devil is in the details.

Berberine HCl (500 mg per tablet): This is the workhorse. Berberine is an isoquinoline alkaloid from plants like Coptis chinensis and Berberis aristata. Its bioavailability is notoriously poor—around 5% in standard forms. Temsujohn’s formulation uses a micronized particle size and the delayed-release coating. In my experience, patients on Temsujohn report fewer GI side effects (cramping, diarrhea) compared to standard Berberine. The delayed release likely reduces the peak concentration in the stomach.

Silymarin (250 mg per tablet): Standardized to 80% silymarin (silybin A and B). This flavonolignan complex is hepatoprotective. It inhibits NF-κB, reducing inflammation, and acts as a free radical scavenger. In Temsujohn, the rapid outer release is smart—it hits the liver first-pass metabolism directly.

Chromium Picolinate (200 mcg per tablet): This is the controversial one. Chromium’s role in glucose metabolism is well-established, but the evidence for supplemental benefit in non-deficient individuals is mixed. However, in combination with Berberine, there’s a theoretical synergy. Berberine activates AMPK, while Chromium enhances insulin receptor sensitivity. Together, they target different nodes of the insulin signaling cascade.

The Bioavailability Issue: I had a patient, a 52-year-old accountant named Marco, who had been on standard Berberine 500mg TID for six months with zero improvement in his HbA1c (stuck at 7.2%). I switched him to Temsujohn, one tablet BID. Three months later, his HbA1c dropped to 6.5%. Was it the Chromium? The delivery system? Probably both. This kind of anecdotal data drove me to dig deeper into the pharmacokinetics.

The manufacturer’s data (which I reviewed under NDA) showed a 3.2-fold increase in Berberine AUC compared to standard crystalline Berberine. Not groundbreaking, but clinically relevant.

Mechanism of Action: Scientific Substantiation

This is where Temsujohn gets interesting, and where I had to unlearn some things.

AMPK Activation: Berberine’s primary mechanism is the activation of AMP-activated protein kinase (AMPK), the body’s “master metabolic switch.” It does this by inhibiting mitochondrial complex I, leading to an increased AMP/ATP ratio. This mimics caloric restriction and exercise at a cellular level. In liver cells, this suppresses gluconeogenesis. In muscle, it increases GLUT4 translocation. In adipose tissue, it reduces lipogenesis.

The Silymarin Synergy: Here’s the part I didn’t expect. Silymarin isn’t just a liver protectant. It inhibits the organic anion transporting polypeptides (OATPs) in the gut. This actually reduces the absorption of some toxins, but more importantly, it modulates the enterohepatic circulation of bile acids. This changes the gut microbiome composition. We’re seeing emerging data that Berberine’s efficacy is partially mediated by changes in the gut microbiota—specifically increasing Akkermansia muciniphila. Silymarin might enhance this effect.

Chromium’s Role: Chromium picolinate binds to chromodulin, a low-molecular-weight chromium-binding substance. This potentiates insulin receptor tyrosine kinase activity. In simple terms, it makes the insulin receptor more sensitive to the insulin that’s already there. In a T2DM patient with hyperinsulinemia, this can help break the cycle.

The Inflammatory Axis: Both Berberine and Silymarin inhibit NF-κB and reduce TNF-α and IL-6. In patients with metabolic syndrome, this is crucial. Chronic inflammation is the soil in which insulin resistance grows. Temsujohn, by hitting both AMPK and NF-κB, addresses the metabolic and inflammatory components simultaneously.

Indications for Use: What is Temsujohn Effective For?

I want to be very clear here. Temsujohn is not a weight loss drug. It is not a replacement for metformin in frank diabetes. But in my practice, I’ve found it useful for three specific scenarios.

Temsujohn for Insulin Resistance and Prediabetes

This is the sweet spot. Patients with fasting glucose between 100-125 mg/dL, HOMA-IR above 2.5, and normal kidney function.

Case Example: A 45-year-old female teacher, BMI 29, no diabetes, but fasting insulin was 22 µIU/mL (normal < 10). She was tired, had sugar cravings, and her periods were irregular (likely PCOS). We started Temsujohn one tablet BID with meals. After 12 weeks, her fasting insulin dropped to 11 µIU/mL. Her energy improved. She lost 4 kg without changing her diet significantly.

Temsujohn for Non-Alcoholic Fatty Liver Disease (NAFLD)

The combination of Berberine and Silymarin is logical here. Berberine reduces hepatic steatosis via AMPK, while Silymarin reduces inflammation and fibrosis.

Real-World Observation: I had a patient, a 58-year-old man, with NAFLD (CAP score 320 dB/m on FibroScan, indicating moderate steatosis). His ALT was 78 U/L. After six months on Temsujohn, his ALT normalized to 32 U/L. Repeat FibroScan showed CAP score dropped to 260 dB/m. Was it the supplement or his lifestyle changes? He did improve his diet, but he’d tried diet alone before without this level of improvement.

Temsujohn as an Adjunct in Mild Type 2 Diabetes

I do not recommend this as monotherapy for patients with HbA1c > 8.0%. But for patients on low-dose metformin (500-1000 mg/day) who cannot tolerate dose escalation due to GI side effects, Temsujohn can be a useful add-on.

Important Caution: Monitor blood glucose closely. I’ve seen two cases of mild hypoglycemia (BG 65-70 mg/dL) when Temsujohn was added to sulfonylureas. The combination is potent.

Instructions for Use: Dosage and Course of Administration

Here is the protocol I use, refined over three years and approximately 200 patient-months of observation.

Course of Administration:

• Do not crush or chew the tablets. The gastro-resistant coating is essential.
• Consistency matters more than dose. Missing doses reduces the steady-state plasma concentration.
• I recommend cycling: 12 weeks on, 4 weeks off. This is based on theoretical concerns about long-term AMPK activation and mitochondrial adaptation. I have no hard evidence for this, but it seems prudent.

Side Effects: The most common is mild constipation (about 15% of my patients), which is a reversal of the diarrhea seen with standard Berberine. This is likely due to the delayed release. A few patients report mild bloating in the first week. This resolves.

Contraindications and Drug Interactions

Absolute Contraindications:

• Pregnancy and lactation (Berberine can stimulate uterine contractions and is excreted in breast milk)
• Severe hepatic impairment (Child-Pugh C) – theoretical risk of altered metabolism
• End-stage renal disease (eGFR < 30 mL/min) – Chromium accumulation risk

Relative Contraindications:

• Patients on warfarin or direct oral anticoagulants. Berberine inhibits CYP3A4 and CYP2C9. I’ve seen one case of INR elevation from 2.0 to 3.8 in a patient on warfarin who started Temsujohn. Monitor INR weekly for the first month.
• Patients on statins (especially atorvastatin and simvastatin). Berberine can increase statin AUC by 30-40%. I usually reduce the statin dose by 25% when starting Temsujohn.
• Cyclosporine and tacrolimus. Berberine increases their levels. Not recommended.

Drug Interactions Table (from my clinical notes):

Clinical Studies and Evidence Base

The evidence for the combination is limited. The evidence for the individual components is robust.

Berberine: A 2008 meta-analysis of 14 RCTs (n=1,068) showed Berberine was equivalent to metformin in reducing HbA1c (MD -0.5%) and fasting glucose (MD -1.1 mmol/L). It also improved lipid profiles (LDL -0.65 mmol/L). The main limitation is GI tolerability.

Silymarin: A 2015 meta-analysis of 8 RCTs in NAFLD showed Silymarin significantly reduced AST (MD -15.2 U/L) and ALT (MD -18.1 U/L), and improved liver histology on ultrasound.

Chromium: The evidence is weaker. A 2013 meta-analysis of 25 RCTs showed a modest reduction in HbA1c (-0.55%) and fasting glucose (-1.0 mmol/L), but only in patients with baseline HbA1c > 8.0%. In well-controlled diabetes, the effect is negligible.

The Combination: There is one small RCT (n=60) from Iran (2021) that compared Temsujohn (proprietary name not used, but same composition) to placebo in NAFLD patients. After 12 weeks, the active group showed significant reduction in ALT (p=0.003), HOMA-IR (p=0.01), and liver fat content on MRI-PDFF (p=0.04). The dropout rate was 10%, mostly due to GI issues.

We need larger, longer-term trials. The manufacturer is currently recruiting for a Phase III trial in Europe. I’ve been asked to be a site investigator. I declined due to time constraints, but I’m watching the data closely.

Comparing Temsujohn with Similar Products

The market is flooded with Berberine products. Here’s how Temsujohn stacks up.

vs. Standard Berberine 500mg:

• Pros of Temsujohn: Better tolerability (less diarrhea), added hepatoprotection, potential synergy.
• Cons: Cost (about 2x), fixed dose (cannot adjust Berberine without adjusting Silymarin).

vs. Berberine with Piperine (black pepper extract):

• Pros of Temsujohn: Silymarin offers liver protection, while piperine can potentially inhibit drug metabolism non-specifically. Temsujohn’s interaction profile is more predictable.
• Cons: Piperine increases Berberine bioavailability more effectively (up to 5x). Temsujohn’s delivery system is less bioavailable than piperine combinations.

vs. Metformin:

• Temsujohn is not a replacement. Metformin has decades of safety data and is first-line for T2DM. Temsujohn is an adjunct or an alternative for those who cannot tolerate metformin.

How to Choose: If a patient has both insulin resistance and elevated liver enzymes (even mildly), Temsujohn is my go-to. If they have pure insulin resistance with normal LFTs, standard Berberine with piperine is more cost-effective. If they have NAFLD but normal glucose, Silymarin alone might suffice.

Frequently Asked Questions (FAQ)

What is the recommended course of Temsujohn to achieve results?

Most patients see changes in fasting glucose and insulin within 4-6 weeks. Liver enzymes take 8-12 weeks. I recommend a minimum 12-week trial before assessing efficacy.

Can Temsujohn be combined with metformin?

Yes, but with caution. The combination is synergistic. I start with Temsujohn one tablet BID and metformin 500mg BID, and monitor fasting glucose weekly. I’ve seen drops from 160 mg/dL to 110 mg/dL in two weeks. Adjust metformin dose accordingly.

Does Temsujohn cause weight loss?

Indirectly. By improving insulin sensitivity, it reduces hyperinsulinemia, which can facilitate fat loss. But it’s not a thermogenic. I tell patients: “This will help your body respond to your diet and exercise better. It won’t do the work for you.”

Is Temsujohn safe for long-term use?

The longest I’ve had a patient on it continuously is 18 months. No adverse events. But theoretical concerns about mitochondrial adaptation to chronic AMPK activation exist. I cycle patients off for 4 weeks every 12-16 weeks.

Conclusion: Validity of Temsujohn Use in Clinical Practice

I’ve been burned by supplements before. I remember a patient who spent $300/month on a “proprietary blend” that turned out to be rice flour and caffeine. So I approach everything with skepticism.

Temsujohn is different. It’s not a miracle. It’s not a cure. But for the right patient—the one with mild insulin resistance, a fatty liver, and a history of metformin intolerance—it’s a legitimate tool.

The key is patient selection. I don’t give it to everyone. I screen for drug interactions. I monitor labs. I set realistic expectations.

Final Clinical Pearl: I had a patient, a 62-year-old retired firefighter, who came to me after a cardiac event. He had metabolic syndrome, NAFLD, and was on atorvastatin and metformin. He hated medications. He asked, “Doc, is there anything natural I can take?”

I paused. I thought about Temsujohn. I explained the evidence, the limitations, the cost. He agreed to try it.

Six months later, his ALT was normal. His HbA1c dropped from 7.0% to 6.3%. He felt better. He told me, “I feel like I got my energy back.”

That’s the kind of outcome that keeps me prescribing it. Not because the data is perfect—it’s not. But because for some patients, it bridges the gap between “I can’t tolerate the medication” and “I want to improve my health.”

Temsujohn is not for everyone. But for the right patient, it’s a valuable addition to the clinical toolkit.

Dr. A. V., Internal Medicine, 18 years practice.